Roche: positive results in lung cancer
(CercleFinance.com) - Roche announced on Tuesday that its Alecensa tablet reduced the risk of death in a group of patients with non-small cell lung cancer (NSCLC) by 76%, a level the biopharmaceutical group considers "unprecedented".
The Swiss company says that the Phase III trial also demonstrated that the drug reduced the risk of disease recurrence by 76% compared to chemotherapy alone in patients with ALK-positive NSCLC following surgery.
By way of indication, around 5% of NSCLC patients express an ALK gene fusion.
Following these results, Roche says it is working with health authorities worldwide to bring Alecensa, discovered by its Japanese subsidiary Chugai, to market "as soon as possible" in this indication.
The treatment is currently available in around 100 countries, but only for patients with advanced (metastatic) ALK-positive NSCLC.
Despite this announcement, Roche shares were down 0.6% on Wednesday morning on the Zurich stock exchange.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Swiss company says that the Phase III trial also demonstrated that the drug reduced the risk of disease recurrence by 76% compared to chemotherapy alone in patients with ALK-positive NSCLC following surgery.
By way of indication, around 5% of NSCLC patients express an ALK gene fusion.
Following these results, Roche says it is working with health authorities worldwide to bring Alecensa, discovered by its Japanese subsidiary Chugai, to market "as soon as possible" in this indication.
The treatment is currently available in around 100 countries, but only for patients with advanced (metastatic) ALK-positive NSCLC.
Despite this announcement, Roche shares were down 0.6% on Wednesday morning on the Zurich stock exchange.
Copyright (c) 2023 CercleFinance.com. All rights reserved.